Key result
Critical appraisal of a cohort study on left atrial enlargement and 1-year cerebrovascular events highlights the need to integrate cardiovascular-kidney-metabolic interactions for risk stratification.
Answers are grounded in this paper and cite their sources.
This editorial highlights the need to integrate cardiovascular-kidney-metabolic interactions and additional atrial cardiomyopathy markers when assessing cerebrovascular risk in patients with left atrial enlargement.
We critically appraise a large prospective cohort study on left atrial enlargement and 1-year cerebrovascular events in patients without atrial fibrillation. While the study provides valuable short-term prognostic evidence, we highlight four key considerations: the overlooked impact of cardiovascular-kidney-metabolic interaction, cautious interpretation of sex-specific findings due to lacking formal interaction tests, potential indication bias in antiplatelet protection claims, and the value of additional atrial cardiomyopathy markers beyond left atrial volume index. Addressing these aspects would enhance risk stratification and translational applicability.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) conducted an editorial in Left atrial enlargement in patients without atrial fibrillation. Critical appraisal of a cohort study on left atrial enlargement and 1-year cerebrovascular events highlights the need to integrate cardiovascular-kidney-metabolic interactions for risk stratification.
Synapse has enriched 5 related papers. Consider them for comparative context: